Drug Combo Improves Activity in Heart Failure Patients

Treatment with sacubitril/valsartan (Entresto) improved several types of physical and social activities in heart failure patients with reduced ejection fraction compared with enalapril.

Results published in JAMA Cardiology from a PARADIGM-HF post-hoc analysis demonstrates that treatment with sacubitril/valsartan (Entresto) significantly improved 7 of 10 types of physical and social activities at 8 months in heart failure patients with reduced ejection fraction (HFrEF) versus patients taking enalapril.

The improvement in combined physical and social activity of patients with Entresto versus enalapril was equivalent to a difference of 9 years of aging. The most significant developments included the ability to carry out household chores and the ability to conduct intimate/sexual relationships.

“What we’ve done now is we’ve looked at the way people feel, the symptoms that they have, the limitations that they have, both in physical and social domains,” Scott Solomon, MD, Brigham and Women’s Hospital, told MD Magazine. “What we found is that in virtually all of these domains, all of these questions, patients reported improvement in their limitations if they were randomized to sacubitril compared to those who were randomized to enalapril.”

Click to continue reading on MD Magazine.

Related Videos
Credit: thodonal - stock.adobe.com
Credit: Lars Neumann - stock.adobe.com
Image Credit: Adobe Stock - peterschreiber.media
Conference attendees watching a speaker | Image credit: kasto - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.